Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2019 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants.
Saldaña-Rivera L, Bello M, Méndez-Luna D. Saldaña-Rivera L, et al. J Biomol Struct Dyn. 2019 Oct;37(17):4671-4684. doi: 10.1080/07391102.2018.1558112. Epub 2019 Jan 11. J Biomol Struct Dyn. 2019. PMID: 30558477
Although this resistance was initially attributed to steric blocking by the T790M mutation, experimental studies have demonstrated that differences in the binding affinities of TKIs to T790M and L858R/T790M mutants are more a result of the increased se …
Although this resistance was initially attributed to steric blocking by the T790M mutation, experimental studies have demonstr …
Exploring Gatekeeper Mutations in EGFR through Computer Simulations.
Kannan S, Fox SJ, Verma CS. Kannan S, et al. J Chem Inf Model. 2019 Jun 24;59(6):2850-2858. doi: 10.1021/acs.jcim.9b00361. Epub 2019 May 30. J Chem Inf Model. 2019. PMID: 31099565
In this work we attempt to develop a robust computational protocol for predicting drug resistant mutations at the gatekeeper position (T790) in EGFR. ...However, we found five possible mutations that are well tolerated structurally and energetic …
In this work we attempt to develop a robust computational protocol for predicting drug resistant mutations at the gatekeeper p …
Quantitative prediction of fold resistance for inhibitors of EGFR.
Balius TE, Rizzo RC. Balius TE, et al. Biochemistry. 2009 Sep 8;48(35):8435-48. doi: 10.1021/bi900729a. Biochemistry. 2009. PMID: 19627157 Free PMC article.
Clinical use of ATP-competitive inhibitors of the epidermal growth factor receptor (EGFR) kinase domain can lead to an acquired drug resistant mutant L858R&T790M which dramatically reduces binding affinity relative to a prevalent cancer c
Clinical use of ATP-competitive inhibitors of the epidermal growth factor receptor (EGFR) kinase domain can lead to an …